On Friday, Tarsus Pharmaceuticals Inc (NASDAQ: TARS) was 4.92% up from the session before settling in for the closing price of $31.70. A 52-week range for TARS has been $12.57 – $42.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -17.43% over the last five years. When this article was written, the company’s average yearly earnings per share was at 18.24%. With a float of $31.79 million, this company’s outstanding shares have now reached $34.21 million.
The firm has a total of 244 workers. Let’s measure their productivity. In terms of profitability, gross margin is 92.5%, operating margin of -187.55%, and the pretax margin is -182.14%.
Tarsus Pharmaceuticals Inc (TARS) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Tarsus Pharmaceuticals Inc stocks. The insider ownership of Tarsus Pharmaceuticals Inc is 16.43%, while institutional ownership is 98.59%. The most recent insider transaction that took place on Aug 12 ’24, was worth 912,961. In this transaction Director of this company sold 35,000 shares at a rate of $26.08, taking the stock ownership to the 0 shares. Before that another transaction happened on Aug 12 ’24, when Company’s Director proposed sale 35,000 for $26.85, making the entire transaction worth $939,750.
Tarsus Pharmaceuticals Inc (TARS) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 18.24% per share during the next fiscal year.
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) Trading Performance Indicators
You can see what Tarsus Pharmaceuticals Inc (TARS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 6.99. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 15.18.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.48, a number that is poised to hit -0.94 in the next quarter and is forecasted to reach -2.37 in one year’s time.
Technical Analysis of Tarsus Pharmaceuticals Inc (TARS)
Analysing the last 5-days average volume posted by the [Tarsus Pharmaceuticals Inc, TARS], we can find that recorded value of 0.67 million was lower than the volume posted last year of 0.72 million. As of the previous 9 days, the stock’s Stochastic %D was 95.63%. Additionally, its Average True Range was 1.79.
During the past 100 days, Tarsus Pharmaceuticals Inc’s (TARS) raw stochastic average was set at 58.78%, which indicates a significant decrease from 98.41% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 78.73% in the past 14 days, which was higher than the 65.26% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $27.05, while its 200-day Moving Average is $28.85. Now, the first resistance to watch is $33.93. This is followed by the second major resistance level at $34.60. The third major resistance level sits at $35.81. If the price goes on to break the first support level at $32.04, it is likely to go to the next support level at $30.83. Should the price break the second support level, the third support level stands at $30.16.
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) Key Stats
There are 37,782K outstanding shares of the company, which has a market capitalization of 1.27 billion. As of now, sales total 17,450 K while income totals -135,890 K. Its latest quarter income was 40,810 K while its last quarter net income were -33,290 K.
